| 中文名 | CRINECERFONT、化合物 T31095 |
|---|---|
| 英文名 | 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine |
| 中文别名 | (S)-4-(2-氯-4-甲氧基-5-甲基苯基)-N-(2-环丙基-1-(3-氟-4-甲基苯基)乙基)-5-甲基-N-(丙-2-炔-1-基)噻唑-2-胺 |
| 英文别名 |
Crinecerfont/SSR-125543
Crinecerfont(free base) 2-Thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl (S)-4-(2-chloro-4-methoxy-5-methylphenyl)-N-(2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-(prop-2-yn-1-yl)thiazol-2-amine 4-(2-chloro-4-Methoxy-5-Methyl-phenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-Methyl-phenyl)ethyl]-5-Methyl-N-prop-2-ynyl-1,3-thiazol-2-aMine |
| 描述 | Crinecerfont(SSR-125543)盐酸盐是一种口服有效的非肽CRF1受体拮抗剂。Crinecerfont可用于经典的先天性肾上腺增生症(CAH)研究[1]。 |
|---|---|
| 相关类别 | |
| 靶点 |
IC50: CRF1 receptor |
| 参考文献 |
| 分子式 | C27H28ClFN2OS |
|---|---|
| 分子量 | 483.04000 |
| 精确质量 | 482.15900 |
| PSA | 53.60000 |
| LogP | 7.51740 |